The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

FEBRUARY 26, 2024

Swierk noted that the research on the safety implications of tattoos is still out. Regulation of tattoo inks on the American market is very recent. The tattoo inks available in the American and European markets differ because the latter is subject to stricter regulations, overseen by the European Chemicals Agency.

Ingredients 74

Ingredients Marketing Safety Dermatology 74

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

FEBRUARY 9, 2024

Fully 70% of individuals who live with severe CHE admit to problems in performing everyday activities and suffering disruption in their daily life due to the condition , according to a study in contact dermatitis.” TDD: Why is it so significant that the DELTA FORCE Trial was head-to-head?

Eczema 36

Eczema Marketing Dermatitis Dermatology 36

The Dermatology Digest

AUGUST 13, 2024

The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis. Nemolizumab was generally well tolerated, and its safety profile was consistent with the phase II trial, and between the OLYMPIA 1 and 2 trials.

Dermatitis 36

Dermatitis Clinic Safety Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

JULY 27, 2023

So we just don’t have the standardization of what is being eliminated and no consensus as to what should be eliminated based on safety studies. There’s plenty of natural things that can cause irritant contact dermatitis. We have lots of experience and long-term safety with petrolatum.

Sustainability 36

Sustainability Skincare Safety Ingredients 36

Kind of Stephen

AUGUST 3, 2022

It’s marketed as a soothing ingredient and sometimes, often illegally, as a disinfectant, anti-inflammatory, acne treatment, or something that can “trigger an immune boost…repair and heal skin”. Information from experiments about bleach baths is likely what was warped and inflated into the marketing of skincare sprays with hypochlorous acid.

Sanitation and Sterilization 52

Sanitation and Sterilization Sanitation Eczema Skincare 52

The Dermatology Digest

DECEMBER 20, 2023

Before Harbor Health, he led product and go-to-market functions for CVS’s kidney care and home business units. The company is also conducting a 250-patient phase 2b trial of its topical JAK 1/3 inhibitor, called ATI-1777 in atopic dermatitis. Mr. Raducha-Grace recently served as Head of Clinical Partnerships at Harbor Health.

Dermatology 36

Dermatology Surgery Eczema Office 36

Aesthetics Advisor

JUNE 16, 2024

But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.” Says Dr. Hartman, the lack of safety data and FDA approval are what make exosomes in serums and creams such a contentious trend. freeze) them. Hartman refers to exosomes as "the AI of skin care."

Injections 36

Injections Aromatherapy Ingredients Moisturization 36

Aesthetics Advisor

AUGUST 6, 2023

Spreading throughout the American South, pellagra patients suffered severe symptoms known as the "4 D's": dermatitis, diarrhea, dementia, and death. Amongst them, Niagen® is the only patented form that has gone through the regulatory procedures to assess safety in key markets around the world.

Rosacea 36

Rosacea Diet Dermatitis Safety 36

The Beauty Brains

OCTOBER 17, 2016

According to Fisher’s Contact Dermatitis, acne can result from topical application of cosmetic products via two mechanisms. In most cases, when a company tells you their shampoo or conditioner is “more concentrated” it’s probably just a marketing gimmick. But there are plenty of cheaper peptide products on the market.

Sun Protection 40

Sun Protection Extractions Ingredients Comedogenic 40

The Dermatology Digest

FEBRUARY 8, 2024

Jashin Wu, MD, founder and CEO of the Dermatology Research and Education Foundation in San Diego, CA, says that more psoriasis patients will see improvements in their condition due to the influx of new agents and biosimilars on the market. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

FEBRUARY 19, 2025

Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Alphyns Zabalafin Hydrogel for the treatment of mild-to-moderate atopic dermatitis (AD). Zabalafin Hydrogel is derived from the company’sZabalafin Platformfor multi-target therapeutics.

Dermatitis 69

Dermatitis Safety Clinic Marketing 69

The Dermatology Digest

NOVEMBER 15, 2024

The first subject has been dosed in the Phase III trial of the InnoCare Pharma’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for the treatment of atopic dermatitis (AD) in China. Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.

Dermatitis 36

Dermatitis Safety Marketing Dermatology 36

The Dermatology Digest

APRIL 8, 2025

The first patient has been dosed in Alphyns CLEAR-AD1 Phase 2b clinical trial of Zabalafin Hydrogel in atopic dermatitis (AD) in Australia. In addition to its strong efficacy results, Zabalafin Hydrogel demonstrated excellent safety, side-effect, and patient tolerability. The company anticipates initiating clinical trials in the U.S.

Clinic 36

Clinic Safety Dermatitis Marketing 36

The Dermatology Digest

NOVEMBER 29, 2024

Nemolizumab was well-tolerated, and its safety profile was generally consistent with previous studies. The full results from the Phase 3 OLYMPIA 1 trial were published in JAMA Dermatology. Based on data from the OLYMPIA clinical trial program, nemolizumab has been approved by the U.S.

Clinic 36

Clinic Dermatitis Safety Dermatology 36